ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
Launch of clinical development of avacopan in Hidradenitis Suppurativa (HS), an orphan dermatological disease, remains on track for 2018 –.
Source link
Blog - Latest News
You are here: Home / Uncategorized / ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent ...
Leave a Reply
Want to join the discussion?Feel free to contribute!